Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
18 11 2021
18 11 2021
Historique:
received:
14
04
2021
accepted:
29
10
2021
entrez:
19
11
2021
pubmed:
20
11
2021
medline:
28
12
2021
Statut:
epublish
Résumé
Determination of SARS-CoV-2 antibody responses in the context of pre-existing immunity to circulating human coronavirus (HCoV) is critical for understanding protective immunity. Here we perform a multifactorial analysis of SARS-CoV-2 and HCoV antibody responses in pre-pandemic (N = 825) and SARS-CoV-2-infected donors (N = 389) using a custom-designed multiplex ABCORA assay. ABCORA seroprofiling, when combined with computational modeling, enables accurate definition of SARS-CoV-2 seroconversion and prediction of neutralization activity, and reveals intriguing interrelations with HCoV immunity. Specifically, higher HCoV antibody levels in SARS-CoV-2-negative donors suggest that pre-existing HCoV immunity may provide protection against SARS-CoV-2 acquisition. In those infected, higher HCoV activity is associated with elevated SARS-CoV-2 responses, indicating cross-stimulation. Most importantly, HCoV immunity may impact disease severity, as patients with high HCoV reactivity are less likely to require hospitalization. Collectively, our results suggest that HCoV immunity may promote rapid development of SARS-CoV-2-specific immunity, thereby underscoring the importance of exploring cross-protective responses for comprehensive coronavirus prevention.
Identifiants
pubmed: 34795285
doi: 10.1038/s41467-021-27040-x
pii: 10.1038/s41467-021-27040-x
pmc: PMC8602384
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Spike Glycoprotein, Coronavirus
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6703Subventions
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation)
ID : 31CA30_196906
Organisme : Gilead Sciences (Gilead)
ID : IN-SW-983-6078
Informations de copyright
© 2021. The Author(s).
Références
Elife. 2020 Oct 28;9:
pubmed: 33112236
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
JAMA. 2021 Apr 20;325(15):1535-1544
pubmed: 33704352
Science. 2020 May 8;368(6491):630-633
pubmed: 32245784
J Clin Virol. 2010 Jun;48(2):104-8
pubmed: 20347384
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Nat Commun. 2021 Feb 15;12(1):1018
pubmed: 33589636
Nat Commun. 2021 Apr 9;12(1):2117
pubmed: 33837204
Science. 2021 Oct 8;374(6564):eabh1823
pubmed: 34465633
Cell. 2021 Apr 1;184(7):1858-1864.e10
pubmed: 33631096
J Infect Dis. 2020 Jun 16;222(1):17-25
pubmed: 32296837
Nat Commun. 2021 Feb 19;12(1):1162
pubmed: 33608522
J Exp Med. 2021 Apr 5;218(4):
pubmed: 33533915
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
PLoS One. 2018 Jan 29;13(1):e0191789
pubmed: 29377913
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32692348
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
J Clin Microbiol. 2013 Sep;51(9):3039-46
pubmed: 23850954
Antimicrob Agents Chemother. 2002 Jun;46(6):1896-905
pubmed: 12019106
Science. 2020 Aug 7;369(6504):650-655
pubmed: 32571838
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288661
Nat Commun. 2021 Jun 18;12(1):3781
pubmed: 34145263
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
J Virol. 2021 Jan 13;95(3):
pubmed: 33144321
Science. 2020 Jun 12;368(6496):1274-1278
pubmed: 32404477
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Cell. 2021 Mar 4;184(5):1171-1187.e20
pubmed: 33621484
Science. 2021 Jan 15;371(6526):288-292
pubmed: 33293339
Nat Commun. 2021 Feb 9;12(1):897
pubmed: 33563974
Cell. 2020 Sep 3;182(5):1295-1310.e20
pubmed: 32841599
Vaccine. 2007 May 22;25(21):4324-33
pubmed: 17445955
Cell. 2021 Apr 29;184(9):2523
pubmed: 33930298
Cell Rep Med. 2021 Jan 19;2(1):100189
pubmed: 33495758
Cell Rep Med. 2021 Sep 21;2(9):100405
pubmed: 34485950
Nat Commun. 2021 Feb 8;12(1):844
pubmed: 33558507
Science. 2020 Aug 7;369(6504):643-650
pubmed: 32540902
J Immunol Methods. 2018 Mar;454:48-58
pubmed: 29277486
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Cell. 2020 Aug 20;182(4):828-842.e16
pubmed: 32645326
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
Eur J Clin Microbiol Infect Dis. 2021 May;40(5):1063-1071
pubmed: 33534090
Nat Commun. 2021 May 19;12(1):2938
pubmed: 34011939